160 related articles for article (PubMed ID: 36518452)
1. Modulation of p-glycoprotein-mediated efflux pirarubicin in living multidrug-resistant K562/Dox cell lines by 4-hydroxybenzoic acid and 4-hydroxy-3-methoxybenzoic acid via impairment of the cellular energetic state.
Myint O; Wattanapongpitak S; Kothan S; Udomtanakunchai C; Tima S; Tungjai M
Toxicol Rep; 2022; 9():1443-1451. PubMed ID: 36518452
[TBL] [Abstract][Full Text] [Related]
2. Protein binding of 4-hydroxybenzoic acid and 4-hydroxy-3-methoxybenzoic acid to human serum albumin and their anti-proliferation on doxorubicin-sensitive and doxorubicin-resistant leukemia cells.
Myint O; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Tungjai M
Toxicol Rep; 2021; 8():1381-1388. PubMed ID: 34285884
[TBL] [Abstract][Full Text] [Related]
3. Gallic acid enhances pirarubicin‑induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P‑glycoprotein inhibition.
Aye KT; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Pan J; Tungjai M
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34476509
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Iodinated Radiographic Contrast Media on Multidrug-resistant K562/Dox Cells: Mitochondria Impairment and P-glycoprotein Inhibition.
Supawat B; Udomtanakunchai C; Kothan S; Tungjai M
Cell Biochem Biophys; 2019 Jun; 77(2):157-163. PubMed ID: 30924055
[TBL] [Abstract][Full Text] [Related]
5. Effect of pre-low-dose irradiation on anticancer activities of gallic acid in leukemic K562 and K562/Dox cells: cell viability and cellular energetic state studies.
Aye KT; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Tungjai M
Med Oncol; 2022 Sep; 39(12):229. PubMed ID: 36175689
[TBL] [Abstract][Full Text] [Related]
6. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
[TBL] [Abstract][Full Text] [Related]
7. A Novel Drug Modulator Diarylheptanoid (
Viriyaadhammaa N; Duangmano S; Saiai A; Tungjai M; Dejkriengkraikul P; Tima S; Chiampanichayakul S; Krise J; Anuchapreeda S
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012254
[No Abstract] [Full Text] [Related]
8. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
9. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
[TBL] [Abstract][Full Text] [Related]
10. Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox?
Hu X; Yang H; Pan QR; Zheng S
Chemotherapy; 1995; 41(4):296-305. PubMed ID: 7555211
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
12. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
13. Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.
Tarasiuk J; Stefańska B; Plodzich I; Tkaczyk-Gobis K; Seksek O; Martelli S; Garnier-Suillerot A; Borowski E
Br J Pharmacol; 2002 Mar; 135(6):1513-23. PubMed ID: 11906965
[TBL] [Abstract][Full Text] [Related]
14. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells.
Gatouillat G; Magid AA; Bertin E; El btaouri H; Morjani H; Lavaud C; Madoulet C
Phytomedicine; 2015 Dec; 22(13):1186-94. PubMed ID: 26598918
[TBL] [Abstract][Full Text] [Related]
15. [Effect of cyclosporin A on intracellular accumulation and efflux of drug in K562/DOX cells].
Meng H; Lin X; Lin M
Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):254-6. PubMed ID: 15622758
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
[TBL] [Abstract][Full Text] [Related]
18. Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin.
Yalçintepe L; Halis E; Ulku S
Oncol Lett; 2016 Mar; 11(3):2290-2296. PubMed ID: 26998164
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen.
Wang HW; Ma KL; Liu H; Zhou JY
Aging (Albany NY); 2020 Apr; 12(7):6018-6029. PubMed ID: 32259795
[TBL] [Abstract][Full Text] [Related]
20. 2-Pyrrolinodoxorubicin and its peptide-vectorized form bypass multidrug resistance.
Castex C; Merida P; Blanc E; Clair P; Rees AR; Temsamani J
Anticancer Drugs; 2004 Jul; 15(6):609-17. PubMed ID: 15205606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
